Statistics of bone sarcoma in Japan: report from the population-based cancer registry in Japan.

Bone sarcoma Epidemiology National Cancer Registry Prognosis Sarcoma

Journal

International journal of clinical oncology
ISSN: 1437-7772
Titre abrégé: Int J Clin Oncol
Pays: Japan
ID NLM: 9616295

Informations de publication

Date de publication:
11 Jun 2024
Historique:
received: 09 04 2024
accepted: 01 06 2024
medline: 11 6 2024
pubmed: 11 6 2024
entrez: 10 6 2024
Statut: aheadofprint

Résumé

No previous reports have characterized national bone sarcoma profiles overall. We examined the nationwide statistics for bone sarcoma in Japan using data from the National Cancer Registry (NCR), a population-based cancer registry. We identified 3,755 patients with bone sarcomas entered in the NCR during 2016-2019 using International Classification of Diseases-Oncology, Third Edition codes for cancer topography and morphology. We extracted data on patient demographics, tumor details (reason for diagnosis, tumor location, histology, extent of disease), hospital volume/type, treatment, and prognosis for each patient. Bone sarcoma showed a slight male preponderance. The age distribution peaked at ages 10-20 and 60-80; approximately 44% of patients were aged over 60 years. Chordoma, chondrosarcoma, and malignant fibrous histiocytoma of bone peaked in the elderly, and Ewing's sarcoma peaked in children. Osteosarcoma had two peaks in Japan as well as in Western countries. The most frequent tumor locations were the limb (45%) and the pelvis (21%). Extent of disease was categorized as: "localized" (39%), "regional" (27%), and "distant" (11%). We found significant associations between overall survival and age, tumor location, facility type, hospital volume, histologic subtype, reason for diagnosis, and extent of disease. The latter had the poorest survival. This is the first study to outline the epidemiology, clinical features, treatment, prognosis, and significant factors affecting prognosis of bone sarcoma in Japan using the NCR. Documenting our data regarding elderly patients' outcomes is essential so other countries showing similar population-aging trends can learn from our experiences. Prognostic studies, Level III.

Sections du résumé

BACKGROUND BACKGROUND
No previous reports have characterized national bone sarcoma profiles overall. We examined the nationwide statistics for bone sarcoma in Japan using data from the National Cancer Registry (NCR), a population-based cancer registry.
METHODS METHODS
We identified 3,755 patients with bone sarcomas entered in the NCR during 2016-2019 using International Classification of Diseases-Oncology, Third Edition codes for cancer topography and morphology. We extracted data on patient demographics, tumor details (reason for diagnosis, tumor location, histology, extent of disease), hospital volume/type, treatment, and prognosis for each patient.
RESULTS RESULTS
Bone sarcoma showed a slight male preponderance. The age distribution peaked at ages 10-20 and 60-80; approximately 44% of patients were aged over 60 years. Chordoma, chondrosarcoma, and malignant fibrous histiocytoma of bone peaked in the elderly, and Ewing's sarcoma peaked in children. Osteosarcoma had two peaks in Japan as well as in Western countries. The most frequent tumor locations were the limb (45%) and the pelvis (21%). Extent of disease was categorized as: "localized" (39%), "regional" (27%), and "distant" (11%). We found significant associations between overall survival and age, tumor location, facility type, hospital volume, histologic subtype, reason for diagnosis, and extent of disease. The latter had the poorest survival.
CONCLUSIONS CONCLUSIONS
This is the first study to outline the epidemiology, clinical features, treatment, prognosis, and significant factors affecting prognosis of bone sarcoma in Japan using the NCR. Documenting our data regarding elderly patients' outcomes is essential so other countries showing similar population-aging trends can learn from our experiences.
LEVEL OF EVIDENCE METHODS
Prognostic studies, Level III.

Identifiants

pubmed: 38858229
doi: 10.1007/s10147-024-02566-4
pii: 10.1007/s10147-024-02566-4
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : National Cancer Center Research and Development Funds
ID : 31-A-14
Organisme : National Cancer Center Research and Development Funds
ID : 2022-A-15

Informations de copyright

© 2024. The Author(s) under exclusive licence to Japan Society of Clinical Oncology.

Références

Duchman KR, Gao Y, Miller BJ (2015) Prognostic factors for survival in patients with Ewing’s sarcoma using the surveillance, epidemiology, and end results (SEER) program database. Cancer Epidemiol 39:189–195
doi: 10.1016/j.canep.2014.12.012 pubmed: 25595632
Duchman KR, Gao Y, Miller BJ (2015) Prognostic factors for survival in patients with high-grade osteosarcoma using the Surveillance, Epidemiology, and End Results (SEER) Program database. Cancer Epidemiol 39:593–599
doi: 10.1016/j.canep.2015.05.001 pubmed: 26002013
Duong LM, Richardson LC (2013) Descriptive epidemiology of malignant primary osteosarcoma using population-based registries, United States, 1999–2008. J Registry Manag 40:59–64
pubmed: 24002129
Mirabello L, Troisi RJ, Savage SA (2009) Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer 115:1531–1543
doi: 10.1002/cncr.24121 pubmed: 19197972
Schrager J, Patzer RE, Mink PJ et al (2011) Survival outcomes of pediatric osteosarcoma and Ewing’s sarcoma: a comparison of surgery type within the SEER database, 1988–2007. J Registry Manag 38:153–161
pubmed: 22223058
Ogura K, Higashi T, Kawai A (2017) Statistics of bone sarcoma in Japan: Report from the Bone and Soft Tissue Tumor Registry in Japan. J Orthop Sci 22:133–143
doi: 10.1016/j.jos.2016.10.006 pubmed: 27847134
Ogura K, Higashi T, Kawai A (2017) Statistics of soft-tissue sarcoma in Japan: Report from the Bone and Soft Tissue Tumor Registry in Japan. J Orthop Sci 22:755–764
doi: 10.1016/j.jos.2017.03.017 pubmed: 28601416
Cates JMM (2018) The AJCC 8th Edition Staging System for Soft Tissue Sarcoma of the Extremities or Trunk: A Cohort Study of the SEER Database. J Natl Compr Canc Netw 16:144–152
doi: 10.6004/jnccn.2017.7042 pubmed: 29439175
Stiller CA, Trama A, Serraino D et al (2013) Descriptive epidemiology of sarcomas in Europe: report from the RARECARE project. Eur J Cancer 49:684–695
doi: 10.1016/j.ejca.2012.09.011 pubmed: 23079473
National Cancer Institute (2017) Cancer Stat Facts: Bone and Joint Cancer. National Cancer Institute, Bethesda, MA
Klangjorhor J, Pongnikorn D, Phanphaisarn A et al (2022) An analysis of the incidence and survival rates of bone sarcoma patients in thailand: reports from population-based cancer registries 2001–2015. Cancer Epidemiol 76:102056
doi: 10.1016/j.canep.2021.102056 pubmed: 34798388
Statistics Bureau of Japan. https://www.stat.go.jp/data/jinsui/2022np/index.html
Ishikawa Y, Tsukuma H, Miller RW (1996) Low rates of Paget’s disease of bone and osteosarcoma in elderly Japanese. Lancet 347:1559
doi: 10.1016/S0140-6736(96)90714-X pubmed: 8684133

Auteurs

Koichi Ogura (K)

Department of Musculoskeletal Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan. koogura@ncc.go.jp.

Chigusa Morizane (C)

Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan.

Tomoyuki Satake (T)

Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa-Shi, Chiba, 277-8577, Japan.

Shintaro Iwata (S)

Department of Pediatric Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan.

Yu Toda (Y)

Department of Musculoskeletal Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan.

Shudai Muramatsu (S)

Department of Musculoskeletal Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan.

Eisuke Kobayashi (E)

Department of Musculoskeletal Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan.

Ayumu Arakawa (A)

Department of Pediatric Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan.

Chitose Ogawa (C)

Department of Pediatric Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan.

Yoko Kato (Y)

Rare Cancer Center, National Cancer Center, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan.

Takahiro Higashi (T)

Center for Cancer Control and Information Services, Division of Health Services Research, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan.

Akira Kawai (A)

Department of Musculoskeletal Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan.

Classifications MeSH